For research use only
| Cat No. | ABC-TC5539 |
| Product Type | Human Primary Carcinoma Associated Fibroblasts |
| Cell Type | Fibroblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarcinoma Carcinoma |
| Storage | Liquid Nitrogen |
Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts enable lung tumor microenvironment research, prognosis studies, and therapeutic evaluation.
Human Lung Adenocarcinoma Cancer-Associated Fibroblasts (CAFs) are primary fibroblasts isolated from lung adenocarcinoma tumor tissues and cryopreserved after initial culture, and are often referenced in tumor–stroma research as a representative CAF cell line despite originating as primary CAFs rather than immortalized models. These adherent, spindle-shaped cells express CAF-specific markers including α-SMA, FAP, and vimentin. Functionally, they remodel the tumor microenvironment by secreting cytokines, growth factors, and extracellular matrix components that promote tumor progression, angiogenesis, and metastasis. As a key stromal component in non-small cell lung cancer, particularly adenocarcinoma, CAFs are instrumental in driving therapeutic resistance and cancer cell invasiveness. This physiologically relevant model is ideal for studying tumor-stroma interactions and evaluating anti-cancer strategies targeting the tumor microenvironment. Repeated freeze–thaw cycles should be avoided to preserve cellular integrity and function.
| Species | Human |
| Cat.No | ABC-TC5539 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarcinoma Carcinoma |
| Storage | Liquid Nitrogen |
| Product Type | Human Primary Carcinoma Associated Fibroblasts |
Lung adenocarcinoma-derived CAFs are ideal for studying cancer-stroma crosstalk, tumor growth, and therapeutic resistance. They are widely used in co-culture systems with epithelial tumor cells, 3D tumor spheroid models, and immune cell recruitment assays. These cells support high-content screening, anti-fibrotic drug evaluation, and precision immunotherapy research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts (CAFs) are a type of fibroblast found in the tumor microenvironment of lung adenocarcinoma. They play a significant role in supporting tumor growth, invasion, and metastasis by interacting with cancer cells and modifying the extracellular matrix.
Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts (CAFs) differ from normal fibroblasts in that they are activated and often exhibit altered gene expression, enhanced secretion of growth factors, cytokines, and proteases. These changes enable them to support tumor progression, whereas normal fibroblasts typically function in tissue repair and maintenance.
In lung adenocarcinoma, Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts contribute to tumor growth and metastasis by promoting angiogenesis, suppressing immune responses, remodeling the extracellular matrix, and facilitating cancer cell invasion and migration. They are key players in creating a tumor-promoting environment.
Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts are identified by their expression of specific markers such as alpha-smooth muscle actin (α-SMA), fibroblast activation protein (FAP), and platelet-derived growth factor receptor (PDGFR). These markers help distinguish them from normal fibroblasts and other cell types in the tumor microenvironment.
Yes, targeting Human Lung Adenocarcinoma Carcinoma Associated Fibroblasts is an emerging strategy in cancer therapy. Since CAFs play a crucial role in supporting tumor growth and resistance to therapy, disrupting their function or altering their interactions with cancer cells could enhance the effectiveness of existing treatments and reduce tumor progression.